Compare Roundhill Magnificent Seven ETF (MAGS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.31 (market cap $5.84B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13.1× Roundhill Magnificent Seven ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MAGS | REGN | |
|---|---|---|
Market Cap | $5.84B | $76.40B |
Volume | 1,765,091 | 626,381 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $852.03 |
52-Week Low | $55.39 | $557.73 |
Typical Hold Time | 36 Days | 107 Days |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to seven mega-cap tech leaders and has delivered 181% returns since launch, though it trails the S&P 500 in 2026 with just 2% YTD gains. Recent news highlights AI-driven momentum but also concerns about the 'Magnificent Seven' theme fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but investors face concentration risk in tech and underperformance versus broader markets. Key risks include aggressive AI spending impacting cash flows and shifting investor preference toward semiconductors. Analyst sentiment is mixed, balancing long-term growth prospects against near-term valuation concerns and market rotation trends.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
